CRANBURY, N.J. & SHANGHAI–(BUSINESS WIRE)–Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first patient in China in a Phase 1 study of AC0682, an orally bioavailable chimeric degrader molecule designed to target ER? protein with high potency and selectivity.
�The initiation of this study marks the first program from our chimeric degrader portfolio to enter the clinic in China, after the initiation of AC0682 Phase 1 study in the US late last year and the IND clearance by the China National Medical Products Administration (NMPA) earlier this year, said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc. Breast cancer is the most common cancer type among Chinese women. We look forward to accelerating the development of AC0682 globally with the goal of bringing transformative medicines to patients worldwide.
The Phase 1 study in China will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0682 treatment in Chinese patients with ER-positive breast cancer. Additional information on this clinical trial can be found on www.clinicaltrials.gov (NCT05489679).
About AC0682
AC0682 is an investigational orally bioavailable, chimeric degrader of ER? for the potential treatment of ER-positive breast cancers. ER? is a hormone-regulated transcription factor that plays a critical role in breast cancer initiation and proliferation, and nearly 80% of breast cancers express ER?. In preclinical studies, AC0682 demonstrated potent and selective ER? protein degradation with favorable pharmacological properties, as well as promising anti-tumor activity in ER-positive animal tumor models.
About Accutar Biotechnology, Inc.
Accutar is a clinical stage biotech company focused on AI-empowered drug discovery, and its application to the discovery and development of clinically differentiated medicines.
Be transformative. For patients.
To learn more about Accutar, please visit us at www.accutarbio.com.
Contacts
Jiaqi Ren
media@accutarbio.com
LambdaTest Tunnel boosts its security and performance with SOCKS5 proxy and HTTP/2 support, enabling secure,…
WUHAN, China--(BUSINESS WIRE)--With the acceleration of globalization, China automobile industry is facing new opportunities for…
NEW YORK--(BUSINESS WIRE)--FOX News Media, in partnership with the National Merit Scholarship Program, has selected…
SHANGHAI & SEOUL, South Korea & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shaperon, Inc. (Kosdaq: 378800), a biotechnology company…
Purchases Demonstrate Lessor’s Continued Strong Activity in Secondary Market DUBLIN--(BUSINESS WIRE)--#AndyCronin--CDB Aviation, a wholly owned…
Company in discussions with U.S. Food and Drug Administration regarding first-ever human clinical trial as…
